A HIV Vaccine Proves Elusive Again As J&J Study Fails

Virus Continues To Evade Vaccine Developers

Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.

Janssen Leiden Netherlands
The HIV vaccine candidate used the same Ad26 viral vector as in J&J's COVID-19 vaccine - but found HIV a far more difficult virus to protect against.

Hopes that a vaccine to prevent HIV infection could finally be around the corner have been dashed after the failure of Johnson & Johnson's large-scale Phase IIb study in sub-Saharan Africa.

The primary analysis of the Imbokodo trial (also known as HVTN 705/HPX2008) in young women at risk of infection found...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category